Applicability of a combination of hemoglobin A1c and fasting plasma glucose in population-based prediabetes screening

Journal of Diabetes

Volumn 4, Issue 4, 2012, Pages 407-416

  Okosun, Ike S ^a   Davis Smith, Monique ^b   Paul Seale, J ^b   Ngulefac, John ^c  

^a GEORGIA STATE UNIVERSITY   (United States)

^b MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SciMetrika   (United States)

Author keywords

Diabetes mellitus; Glycated hemoglobin; Glycemia; Glycemic index; Impaired glucose tolerance

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; CAUCASIAN; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HISPANIC; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; ETHNIC GROUPS; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; NUTRITION SURVEYS; PREDIABETIC STATE; PREVALENCE;

EID: 84870377299     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2012.00188.x     Document Type: Article

References (30)

1. National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation. National diabetes fact sheet, 2011. Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf (accessed 28December 2011).
2. A1c as risk factors for Type 2 diabetes. Diabet Med. 2008; 25: 1157-63.
3. A1c in predicting progression to diabetes in French men and women: Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care. 2006; 29: 1619-25.
4. A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am J Med. 2007; 120: 720-7.
5. A1c independent of glycemia?J Diabetes Sci Technol. 2009; 3: 656-60.
6. Gerstein HC, Swedberg K, Carlsson J et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: An analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med. 2008; 168: 1699-704.
7. A1c and risk of all-cause mortality among US adults without diabetes. Circ Cardiovasc Qual Outcomes. 2010; 3: 661-7.
8. A1c with cardiovascular disease and mortality in adults: The European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004; 141: 413-20.
9. National Health and Nutrition Examination Survey. Available from: http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/current_nhanes_07_08.htm (accessed 16 March 2011).
10. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010; 303: 235-41.
11. Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA. 2010; 303: 242-9.
12. Shah BV, Barnwell BG, Bieler G. SUDAAN Users manual. 1996. Research Triangle Park, Research Triangle, NC.
13. Fleiss JL. Statistical Methods for Rates and Proportion. Wiley, New York, 1981.
14. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27: 1047-53.
15. Narayan KM, Boyle JP, Geiss LS, Saaddine JR, Thompson JT. Impact of recent increase in incidence on future diabetes burden.US, 2005-2050. Diabetes Care. 2006; 29: 2114-6.
16. Cowie CC, Rust KF, Byrd-Holt DD et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care. 2006; 29: 1263-8.
17. A1C assay into estimated average glucose values. Diabetes Care. 2008; 31: 1473-8.
18. 1C in adults without a history of diabetes in the U.S. Diabetes Care. 2009; 32: 828-33.
19. A1c, and 1, 5-anhydroglucitol in over 2000 patients with type2 diabetes. J Clin Endocrinol Metab. 2009; 94: 1689-94.
20. Herman WH, Ma Y, Uwaifo G et al. Diabetes Prevention Program Research Group. Differences in A1c by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care. 2007; 30: 2453-7.
21. A1c predicts the progression to diabetes in Chinese subjects. Diabetes Care. 2000; 23: 1770-3.
22. Saudek CD, Herman WH, Sacks DB, Bergenstal RM, Edelman D, Davidson MB. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab. 2008; 93: 2447-53.
23. Cosson E, Nguyen MT, Hamo-Tchatchouang E et al. What would be the outcome if the American Diabetes Association recommendations of 2010 had been followed in our practice in 1998-2006?Diabet Med. 2011; 28: 567-74.
24. A1c in the screening of diabetes and impaired glucose tolerance. Acta Diabetol. 2010; 47: 231-6.
25. A1c in the Diabetes Control and Complications Trial. Diabetes Care. 2002; 25: 275-8.
26. Delpierre G, Collard F, Fortpied J, Van Schaftingen E. Fructosamine 3-kinase is involved in an intracellular deglycation pathway in human erythrocytes. Biochem J. 2002; 365(Pt 3): 801-8.
27. A1c as a screening tool for detection of Type 2 diabetes: A systematic review. Diabet Med. 2007; 24: 333-43.
28. Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med. 2007; 23: 167.
29. Knuiman MW, Divitini ML, Buzas JS, Fitzgerald PE. Adjustment for regression dilution in epidemiological regression analyses. Ann Epidemiol. 1998; 8: 56-63.
30. Spearman C. The proof and measurement of association between two things: By C. Spearman, 1904. Am J Psychol. 1987; 100: 441-71.